@article{f7ece1fe72bf42b8986db38f8bb15b74,
title = "Disease-specific ADRs of TNF-α inhibitors as reported by patients with inflammatory rheumatic diseases: a registry-based prospective multicenter cohort study",
abstract = "Background: The extent to which adverse drug reactions (ADRs) of biologics differ per immune-mediated inflammatory disease (IMID), and the relevance of tailoring ADR information per IMID is not fully investigated. We aimed to compare patient-reported ADRs attributed to adalimumab and etanercept between different inflammatory rheumatic diseases (IRDs). Research design and methods: ADR reports from IRD patients were extracted from the Dutch Biologic Monitor. ADR frequencies were compared using Fischer–Freeman–Halton exact test and the influence of covariates was assessed using binomial logistic regression. A total, of 729 participants were included, of which 354 participants reported 887 unique ADRs. ADR frequencies were not significantly different between the IRDs. Rheumatoid arthritis and ankylosing spondylitis including axial spondyloarthritis patients had an increased risk of ADRs related to {\textquoteleft}Respiratory, thoracic and mediastinal disorders{\textquoteright} and as compared to psoriatic arthritis patients. Etanercept use, combination therapy with methotrexate and/or corticosteroids, and age also influenced the risk of reporting specific ADRs. Conclusions: There were no differences in frequencies and nature of patient-reported ADRs attributed to adalimumab and etanercept between different IRDs. However, more research is needed to align patients{\textquoteright} and health-care professionals{\textquoteright} perspectives to improve knowledge on disease-specific ADRs.",
keywords = "Adverse drug reactions, anti-TNF therapy, bDMARD, inflammatory rheumatic diseases, patient perspective",
author = "Roest, {Lieke H.} and Kosse, {Leanne J.} and {van Lint}, {Jette A.} and Gosselt, {Helen R.} and Scholl, {Joep H. G.} and {van Puijenbroek}, Eug{\`e}ne and Vonkeman, {Harald E.} and Tas, {Sander W.} and Nurmohamed, {Michael T.} and {van den Bemt}, {Bart J. F.} and Jessurun, {Naomi T.}",
note = "Funding Information: HE Vonkeman reports service on advisory boards, or as speaker, or consultant for AbbVie, Amgen, AstraZeneca, BMS, Celgene, Celltrion, Galapagos, Gilead, GSK, Janssen-Cilag, Lily, MSD, Novartis, Pfizer, Roche, Sanofi-Genzyme, all outside the submitted work. SW Tas reports grants and/or persona fees from AbbVie, Arthrogen, AstraZeneca, BMS, Celgene, Galapagos, GSK, MSD, Pfizer, Roche, Sanofi-Genzyme, all outside the submitted work. MT Nurmohamad reports grants and personal fees from AbbVie and Eli Lilly, and grants from BMS, Amgen, and Pfizer, outside the submitted work. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Funding Information: A peer reviewer on this manuscript has disclosed research grants from Pfizer, BMS, and AbbVie. All other peer reviewers on this manuscript have no relevant financial or other relationships to disclose. Publisher Copyright: {\textcopyright} 2022 Netherlands Pharmacovigilance Centre Lareb. Published by Informa UK Limited, trading as Taylor & Francis Group.",
year = "2022",
doi = "https://doi.org/10.1080/14740338.2022.2115479",
language = "English",
journal = "Expert opinion on drug safety",
issn = "1474-0338",
publisher = "Informa Healthcare",
}